

Ethiopia

Population 2017

105 million

Estimates of TB burden*, 2017	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	25 (16–37)	24 (15–35)
Mortality (HIV+TB only)	3.6 (2.5–5)	3.5 (2.4–4.8)
Incidence (includes HIV+TB)	172 (121–232)	164 (115–221)
Incidence (HIV+TB only)	12 (8.6–17)	12 (8.2–16)
Incidence (MDR/RR-TB)**	5.5 (2.9–8.9)	5.2 (2.8–8.4)

Estimated TB incidence by age and sex (thousands)*, 2017			
	0-14 years	> 14 years	Total
Females	9.5 (8.7–10)	69 (55–83)	78 (61–95)
Males	10 (9.6–11)	83 (65–102)	94 (71–116)
Total	20 (18–22)	152 (106–198)	172 (121–232)

TB case notifications, 2017	
Total cases notified	117 705
Total new and relapse	116 725
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	86%
- % pulmonary	69%
- % bacteriologically confirmed among pulmonary	58%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2017	68% (50–96)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2017	0.17 (0.1–0.26)

TB/HIV care in new and relapse TB patients, 2017		
	Number	(%)
Patients with known HIV-status who are HIV-positive	7 272	7%
- on antiretroviral therapy	6 673	92%

Drug-resistant TB care, 2017			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			2 700 (1 700–3 700)
Estimated % of TB cases with MDR/RR-TB	2.7% (1.6–4.1)	14% (6.7–25)	
% notified tested for rifampicin resistance			38 501
MDR/RR-TB cases tested for resistance to second-line drugs			205
Laboratory-confirmed cases		MDR/RR-TB: 680, XDR-TB: 4	
Patients started on treatment ****		MDR/RR-TB: 680, XDR-TB: 4	

Treatment success rate and cohort size		
	Success	Cohort
New cases registered in 2016	90%	123 004
Previously treated cases registered in 2016		
HIV-positive TB cases registered in 2016		
MDR/RR-TB cases started on second-line treatment in 2015	75%	660
XDR-TB cases started on second-line treatment in 2015		

TB preventive treatment, 2017	
% of HIV-positive people (newly enrolled in care) on preventive treatment	45%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	11% (9.9–12)

TB financing, 2018	
National TB budget (US\$ millions)	93
Funding source: 11% domestic, 33% international, 56% unfunded	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2017




Treatment success rate (%)



— New cases
— Previously treated cases
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



— Unfunded
— Funded internationally
— Funded domestically